Viral Hepatitis

14,000,000 Leading Edge Experts on the ideXlab platform

Scan Science and Technology

Contact Leading Edge Experts & Companies

Scan Science and Technology

Contact Leading Edge Experts & Companies

The Experts below are selected from a list of 243 Experts worldwide ranked by ideXlab platform

Pierre Van Damme - One of the best experts on this subject based on the ideXlab platform.

  • Burden and prevention of Viral Hepatitis in Bulgaria.
    Vaccine, 2011
    Co-Authors: David Fitzsimons, Mira Kojouharova, Johannes Hallauer, Greet Hendrickx, Alex Vorsters, Pierre Van Damme
    Abstract:

    A meeting of the Viral Hepatitis Prevention Board in Sofia, Bulgaria on 24-25 March 2011 reviewed the burden and prevention of Viral Hepatitis in the country. It examined the organization and funding of the health system, the surveillance systems for infectious diseases, and the epidemiology of Viral Hepatitis, especially the impact of the universal neonatal Hepatitis B immunization programme introduced almost 20 years ago. It also looked at the implementation of new prevention strategies, such as the health mediator concept, as well as control measures and monitoring systems. Participants discussed the successes, the way forward and possible obstacles.

  • Prevention of Viral Hepatitis in Italy.
    Vaccine, 2004
    Co-Authors: David Fitzsimons, Guido François, Paolo Bonanni, Alfonso Mele, Alessandro Zanetti, Tommaso Stroffolini, Pietro Crovari, Pierre Van Damme
    Abstract:

    The overall situation on Viral Hepatitis prevention and control in Italy was reviewed and evaluated at a Viral Hepatitis Prevention Board (VHPB) meeting in Catania, Sicily, on 7-8 November 2002. Several specific conclusions, drawn from the presentations and discussions, were considered to constitute an example of how to handle these issues in other European and industrialized countries.

Janice Main - One of the best experts on this subject based on the ideXlab platform.

David Fitzsimons - One of the best experts on this subject based on the ideXlab platform.

  • Burden and prevention of Viral Hepatitis in Bulgaria.
    Vaccine, 2011
    Co-Authors: David Fitzsimons, Mira Kojouharova, Johannes Hallauer, Greet Hendrickx, Alex Vorsters, Pierre Van Damme
    Abstract:

    A meeting of the Viral Hepatitis Prevention Board in Sofia, Bulgaria on 24-25 March 2011 reviewed the burden and prevention of Viral Hepatitis in the country. It examined the organization and funding of the health system, the surveillance systems for infectious diseases, and the epidemiology of Viral Hepatitis, especially the impact of the universal neonatal Hepatitis B immunization programme introduced almost 20 years ago. It also looked at the implementation of new prevention strategies, such as the health mediator concept, as well as control measures and monitoring systems. Participants discussed the successes, the way forward and possible obstacles.

  • Prevention of Viral Hepatitis in Italy.
    Vaccine, 2004
    Co-Authors: David Fitzsimons, Guido François, Paolo Bonanni, Alfonso Mele, Alessandro Zanetti, Tommaso Stroffolini, Pietro Crovari, Pierre Van Damme
    Abstract:

    The overall situation on Viral Hepatitis prevention and control in Italy was reviewed and evaluated at a Viral Hepatitis Prevention Board (VHPB) meeting in Catania, Sicily, on 7-8 November 2002. Several specific conclusions, drawn from the presentations and discussions, were considered to constitute an example of how to handle these issues in other European and industrialized countries.

Fabien Zoulim - One of the best experts on this subject based on the ideXlab platform.

  • Progress towards elimination goals for Viral Hepatitis
    Nature reviews. Gastroenterology & hepatology, 2020
    Co-Authors: Andrea L. Cox, Manal H El-sayed, Jia-horng Kao, Jeffrey V. Lazarus, Maud Lemoine, Anna S.f. Lok, Fabien Zoulim
    Abstract:

    The global burden of Viral Hepatitis is substantial; in terms of mortality, Hepatitis B virus and Hepatitis C virus infections are on a par with HIV, malaria and tuberculosis, among the top four global infectious diseases. In 2016, the 194 Member States of the World Health Organization committed to eliminating Viral Hepatitis as a public health threat by 2030, with a particular focus on Hepatitis B virus and Hepatitis C virus infection. With only 10 years to go until the 2030 deadline is reached, and although much progress has been made towards elimination, there are still some important gaps in terms of policy and progress. In this Viewpoint, we asked a selection of scientists and clinicians working in the Viral Hepatitis field for their opinions on whether elimination of Viral Hepatitis by 2030 is feasible, what the key areas of progress are and what the focus for the next 10 years and beyond should be for Viral Hepatitis elimination.

  • New challenges in Viral Hepatitis
    Gut, 2012
    Co-Authors: David L. Thomas, Fabien Zoulim
    Abstract:

    Over the past few decades there has been remarkable progress in Viral Hepatitis. Beginning with discovery of the Viral agents, we now have reliable methods to diagnose and monitor all Hepatitis virus infections, as well significant advances in treatment and prevention. Nonetheless, important challenges remain. This supplement to Gut looks forward to the next generation of challenges in the field of Viral Hepatitis, and this introductory article highlights several key issues.

Tanay Surjan - One of the best experts on this subject based on the ideXlab platform.

  • Study of Lipid Profile in Acute Viral Hepatitis
    International Journal of Research, 2019
    Co-Authors: Mahesh Dave, Shubham Sharma, Tanay Surjan
    Abstract:

    Introduction: The Viral Hepatitis is an infectious disease caused by various Hepatitis viruses which affect liver predominantly. Early prediction of impending complication is imperative to modify the cause and prognosis. Viral Hepatitis may disturb metabolism of variable substances. This study ascertains the plasma lipid and lipoprotein pattern in subjects suffering from acute Viral Hepatitis and the change at six weeks follow up. Aims and Objectives: (1) To study the changes in lipid and lipoprotein in acute Viral Hepatitis. (2)To study correlation between lipid and lipoprotein changes and severity of acute Viral Hepatitis. (3) To study the utility of lipid profile changes in prognosis of acute Viral Hepatitis. Materials and Methods: This was hospital based prospective and follow up study, conducted on 50 patients who attended the Medicine department at R N T Medical College and MBGH, Udaipur. Results: Out of 50 patients, majority were in between 21-40 years. 36(72%) were male. 29(58%) were positive for Hepatitis A, 2(4%) for Hepatitis B and 19(38%) for Hepatitis E virus. Total cholesterol, triglyceride, LDL-C and VLDL-C were significantly raised, and HDL-C was significantly decreased at presentation as compared to follow up. There was no significant difference in lipid profile changes between Viral Hepatitis caused by different viruses. HDL-C was also significantly low in subjects who expired in comparison to who recovered. Conclusion: The estimation of lipid levels is required for better assessment of hepatic function; prognostic assessment and management of Viral Hepatitis subjects. Increase in HDL-C during follow up in Viral Hepatitis appears to be a bad prognostic sign.